Hematologic

Our multi-disciplinary approach

We discuss all patients with hematologic malignancies in weekly, or bi-weekly, multi-disciplinary team meetings, involving specialists from the departments of hematology, pathology, radiology, radiotherapy, nuclear medicine and clinical chemistry. Other specialists are involved when indicated. For each patient, the specialized tumor board determines the best treatment approach as well as further actions to be taken prior to the start of treatment.

We have state-of-the art radiotherapy treatment techniques at our disposal, such as IMRT and VMAT, as well as high-quality imaging modalities. 

You can find more information about our treatment techniques here.

Proton therapy

As of January 2018 we offer proton therapy for selected indications. Proton therapy is not yet available for patients within the Hematologic Program. In the near future we may offer this treatment to selected patients.

Follow-up

For each patient, we systematically monitor and record side-effects, quality of life and treatment outcome in our Standardized Follow-Up-program. We use these data in our research towards the development of predictive models for radiation-induced side-effects. These models can be used in the selection of the optimal treatment technique. 

M. Beijert, MD

Specialization:
Breast tumors
Hematologic malignancies
Lung tumors

D.M. Busz, MD

Specialization:
Breast tumors
Hematological tumors

A.P.G. Crijns, MD, PhD

Specialization:
Breast tumors
Hematological tumors

The Hematologic Program participates in the follow-up of the EORTC 20971-22997 clinical trial.

There are currently no clinical trials open for patient entry.